Heart Doc VIP with Dr. Joel Kahn cover image

Episode 468: A Trip to the American Heart Association Meeting 2025

Heart Doc VIP with Dr. Joel Kahn

00:00

Oral PCSK9 Inhibitor Shows Promising LDL Drop

Dr. Kahn covers a phase 2 trial of enlissatide, an oral PCSK9 inhibitor that halved LDL, ApoB, and Lp(a) in familial hypercholesterolemia patients.

Play episode from 16:16
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app